Brii Biosciences Limited (2137.HK)
HKD 0.85
(0.0%)
HKD 0.85
(0.0%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -486.49 Million CNY | 58.7% |
| 2022 | -1.17 Billion CNY | 58.43% |
| 2021 | -2.83 Billion CNY | -181.48% |
| 2020 | -1 Billion CNY | -19.09% |
| 2019 | -845.24 Million CNY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -656.25 Million CNY | 0.29% |
| 2024 Q1 | -656.25 Million CNY | -34.89% |
| 2023 Q2 | -479.49 Million CNY | 1.64% |
| 2023 FY | -486.49 Million CNY | 58.7% |
| 2023 Q4 | -486.49 Million CNY | 0.64% |
| 2023 Q3 | -489.65 Million CNY | -2.12% |
| 2023 Q1 | -487.49 Million CNY | 58.61% |
| 2022 Q2 | -2.94 Billion CNY | 0.31% |
| 2022 Q1 | -2.95 Billion CNY | -4.39% |
| 2022 FY | -1.17 Billion CNY | 58.43% |
| 2022 Q4 | -1.17 Billion CNY | 0.8% |
| 2022 Q3 | -1.18 Billion CNY | 59.73% |
| 2021 Q3 | -2.84 Billion CNY | -100.54% |
| 2021 FY | -2.83 Billion CNY | -181.48% |
| 2021 Q1 | 4.69 Billion CNY | 566.75% |
| 2021 Q2 | -1.41 Billion CNY | -130.17% |
| 2021 Q4 | -2.83 Billion CNY | 0.32% |
| 2020 FY | -1 Billion CNY | -19.09% |
| 2020 Q3 | 1.38 Billion CNY | 0.0% |
| 2020 Q4 | -1 Billion CNY | -172.51% |
| 2020 Q1 | 880.35 Million CNY | 0.0% |
| 2019 FY | -845.24 Million CNY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Uni-Bio Science Group Limited | -76.36 Million HKD | -537.031% |
| CK Life Sciences Int'l., (Holdings) Inc. | 5.26 Billion HKD | 109.237% |